Quiz: Adding Trametinib to Dabrafenib for Melanoma With BRAF V600 Mutation

11/26/2019

Recent News

News

Post-Allogeneic Hematopoietic Cell Transplant Gilteritinib Maintenance Demonstrates Benefit for Patients With AML With Detectable FLT3-ITD MRD

05/03/2024

Amber Denham

According to a recent trial, patients with acute myeloid leukemia with FLT3-ITD and measurable residual disease detectable in the peri-transplant period derived benefit from post-transplant gilteritinib, whereas those without detectable MRD...

According to a recent trial,...

05/03/2024

Oncology

News

FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer

05/01/2024

Stephanie Holland

Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.

Based on results from the phase...

05/01/2024

Oncology

News

Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas

04/25/2024

Stephanie Holland

According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.

According to results from the...

04/25/2024

Oncology

News

Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence

04/25/2024

Stephanie Holland

According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...

According to interim analysis...

04/25/2024

Oncology

News

FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

04/25/2024

Stephanie Holland

Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...

Based on results from the...

04/25/2024

Oncology

News

Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

04/24/2024

Stephanie Holland

Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Based on results from the...

04/24/2024

Oncology

News

Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma

04/23/2024

Stephanie Holland

Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...

Results from the phase 2 NRG...

04/23/2024

Oncology

News

FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer

04/23/2024

Stephanie Holland

Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Based on results from the phase...

04/23/2024

Oncology

News

FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer

04/19/2024

Stephanie Holland

Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.

Based on results from the phase...

04/19/2024

Oncology

News

IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization

04/19/2024

Amber Denham

According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...

According to phase 2 results,...

04/19/2024

Oncology